Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory
Karyopharm Therapeutics Compagnie réclamée
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions Lire la suite
I have only been with Karyopharm for less than 3 months, but I am very happy with my decision to join the team!
Qu’est-ce qui est le plus positif à propos de la culture et de l’environnement de votre entreprise?
The excitement associated with the expanded use of XPOVIO.
Qu’est-ce qui vous rend le plus heureux au travail?
Meeting the needs of the teams that I support. Trying to help them be more efficient.
Other Employee Reviews for Karyopharm Therapeutics
×